Friday May 3rd 2024 10:56:22
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares
SIGN IN
SUBSCRIBE

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Articles by: KELVIN PRESCOTT

views

Sell Jim Mellon's Port Erin Biopharma: the facts have changed

I wrote in May of this year that the price of Port Erin Biopharma (PEBI) was trading at a large enough discount to Net Asset Value that it was worth taking a position. At the time, it was trading in the 4-4.5p range; its now at 5.625p in the middle but with a pretty wide spread. But it is time to sell because the facts have changed substantially.

By Kelvin Prescott
2016-12-30 01:01:18

views

Buy Jim Mellon's Port Erin?

Tom Winnifrith recently suggested that Port Erin Biopharma (PEBI) has gone limp because of pessimism about Plethora's premature ejaculation treatment. Cynical Bear says be suspicious of sub-scale investment companies on AIM, full of related party transactions and corporate overheads. So… obviously the moronic thing to do is pile in, right? But still, I am long Port Erin, at least when the price is right (sub 4p). Here’s why.

By Kelvin Prescott
2016-05-20 06:02:00

Page 1 of 1 (2 articles)